Dr. Joshua Arbesman attended the University at Buffalo, School of Medicine and Biomedical Sciences, Buffalo, New York. He completed an Internship in Internal Medicine at State University of New York (SUNY) at Buffalo’s affiliated hospitals. His Dermatology training was completed at University Hospitals Cleveland Medical Center in Cleveland, Ohio. Dr. Arbesman completed a Fellowship training program in Molecular and Investigative Dermatology, as a Post-Doctoral Fellow on T32 NIH Training Grant at Case Western Reserve University/University Hospitals Cleveland Medical Center. He is a member of the American Academy of Dermatology and is a Board Certified Dermatologist.
Dr. Arbesman conducts basic science and clinical research in the areas of melanoma genetics and melanoma drug development. His research centers on the study of melanoma, specifically understanding the genetics of high-risk melanoma families and the design of adjuvant therapies for melanoma management. His current work is involved in next-generation sequencing of high-risk melanoma families to determine novel melanoma susceptibility genes and the characterization of the overall genetics of familial melanoma. Additionally, he examines the repurposing of relatively safe, often previously clinically available, medications, to be used in the adjuvant therapy setting for melanoma patients. Preclinical work on this area is performed in a laboratory setting as preparation for future clinical trials.